Supporting Diversity And Inclusion Goals For Clinical Trials With An Effective Analytics Strategy

The top priority of life sciences organizations is ensuring the safety and efficacy of new clinical treatments in order to improve the health of the individuals and communities they serve. Naturally, the effectiveness of clinical trials hinges on compiling and analyzing data that accurately reflects the target population.

For this reason, participant diversity must be ensured when executing clinical trials, not just for scientific benefits, but also for moral purposes. When a clinical trial participant population consists of individuals from similar backgrounds that largely share the same ethnicity, race, and gender, it limits our understanding of which treatments and medicines are effective for population subgroups. In turn, these subgroups are further marginalized and put at a disadvantage when it comes to receiving safe, effective medical treatment.

The under-representation of racial and ethnic minorities in clinical trials in the United States is too staggering to ignore.